EMBRYONIC DEVELOPMENT DATA ACCESS TO ACTIONABLE DATA PGD / PGS DATA OUR PROPRIETARY DATA ASSETS INCLUDE: EMR DATA CYCLE DATA



Similar documents
Secondary Uses of Data for Comparative Effectiveness Research

An Optum Company. The Journey: From Healthcare To Health

SO, WHAT IS A POOR RESPONDER?

Cardinal Health Specialty Solutions. Cardinal Health Geographic Insights Maximize Market Opportunity with Actionable Insights from Data Visualization

Laboratory Services in Accountable Care Organizations

EMDEON CLINICAL SOLUTIONS

Strengthen Financial Performance: Start with Lab Outreach Gary Palgon, VP Healthcare Solutions Naveen Sarabu, Director Product Management

US Hospital Information Systems Overview and Outlook, Managing Information in an Era of Reform

Impact Intelligence. Flexibility. Security. Ease of use. White Paper

Redefining Role of Business Analyst in the paradigm of Big Data in Healthcare

Access. Action. Insight. Healthcare Analytics and Marketing Communications Consultative, Analytical, and Promotional Solutions

Symposium on RECENT ADVANCES IN ASSISTED REPRODUCTIVE TECHNOLOGY

North Carolina Medicaid Special Bulletin

SCALABLE SYSTEMS LIFE SCIENCE & HEALTHCARE PRACTICES

Measure #130 (NQF 0419): Documentation of Current Medications in the Medical Record National Quality Strategy Domain: Patient Safety

Understanding Diseases and Treatments with Canadian Real-world Evidence

Donut Hole Analysis November 2014

Health Care System. Troyen Brennan, M.D., M.P.H. Executive Vice President & Chief Medical Officer

BioPharma Analytics Informing every move

ICD-10 Transition for Providers: Mitigate the Financial Risks

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Increase success using business intelligence solutions

Revenue Cycle Management (RCM) Market by Product, by Deployment, by Component Global Forecast to 2019

The Cornerstones of Accountable Care ACO

About NEHI: NEHI is a national health policy institute focused on enabling innovation to improve health care quality and lower health care costs.

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q

Summary of results from a clinical doctorate survey

Facing Healthcare Administration Challenges

UTILIZING ACCURATE DATA FOR PHYSICIAN REFERRAL, ACQUISITION & TARGETING

The Business Case for Using Big Data in Healthcare

Accountable Care: Clinical Integration is the Foundation

Hospital IT Expenses and Budgets Related to Clinical Sophistication. Market Findings from HIMSS Analytics

Assisted Reproductive Technologies at IGO

LEVERAGING CLINICAL ANALYTICS TO DESIGN PERSONALISED MEDICINE. Dr. S. B. Bhattacharyya MBBS, MBA Healthcare Domain Consultant

Addressing the State of the Electronic Health Record (EHR)

FINANCIAL INFORMATION FOR PATIENTS

How To Get A Refund On An Ivf Cycle

Virtual Clinic Introduction

Plan and manage clinical trials with clarity and confidence

European IVF Monitoring (EIM) Year: 2008

ACO Toolkit. Face-To-Face Care Coordination Services & Comprehensive Cloud-Based IT Solutions e q h s. o r g

Big Data Analytics in Healthcare In pursuit of the Triple Aim with Analytics. David Wiggin, Director, Industry Marketing, Teradata 20 November, 2014

The State of U.S. Hospitals Relative to Achieving Meaningful Use Measurements. By Michael W. Davis Executive Vice President HIMSS Analytics

Using Evidence-Based Search Marketing to Improve Results and Reduce Costs

QBE A&H, LLC RISK MANAGEMENT GUIDE

A Guide to Marketing Technologies for Distributed Teams

SPECIALTY CASE MANAGEMENT

Swedish RWE a goldmine?

Nutraceutical Medical Research, LLC. By: Latesha Richards, Marketing Coordinator

U.S. Clinical Laboratory and Pathology Testing :

Clinical Policy Committee

Turning Big Data into a competitive advantage? Challenges and opportunities

European IVF Monitoring (EIM) Year: 2010

Values of Healthcare

Big Data Next: Capturing the Promise of Big Data. Big Data Report 2015

Session 2: Digging Deeper APLD, EMR, and Specialty Data Laura Jenkins Jirele

Costs and Limitations Disclosure For MEDITECH s 2014 Edition Certified Products

Mobile Real-Time Bidding and Predictive

Making Sense of Medicare Advantage and Part D Open Enrollment

Achieving Value from Diverse Healthcare Data

In - Vitro Fertilization Handbook

Electronic Medical Records vs. Electronic Health Records: Yes, There Is a Difference. A HIMSS Analytics TM White Paper. By Dave Garets and Mike Davis

Copyright 2009 SAS Institute Inc. All rights reserved. Success With Business Analytics in the New Pharmaceutical Commercial Model.

Make sure you re covered for your biologic medicine!

& Your HIS. Electronic Health Record System. The Dynamic Duo. Everything you need to know to create a Paperless and Process efficient Hospital.

Compensation Survey Physician Executives in Information Technology February 2015

ACCOUNTABLE CARE ANALYTICS: DEVELOPING A TRUSTED 360 DEGREE VIEW OF THE PATIENT

Visual Analytics to Enhance Personalized Healthcare Delivery

INVESTOR PRESENTATION

We ask that you allow our office hours to respond to telephone messages and callbacks.

Preimplantation Genetic Diagnosis (PGD) in Western Australia

Never before has healthcare placed so much emphasis on concentrated,

QUESTIONS FOR The Commonwealth Medical College

ELECTRONIC MEDICAL RECORDS (EMR)

(PACS, EMR, CPOE, RCM,

Epic Systems Corporation - Strategic SWOT Analysis Review

CONCEPT DOES NOT REQUIRE AN UP FRONT DEPOSIT (Except for Standard IVF/ICSI/FET where out of pocket costs must be paid in advance)

The Healthcare Provider Industry Short List: Inpatient Electronic Medical Records Judy Hanover Research Manager, Healthcare Provider IT Strategies

Advanced Solutions for Accountable Care Organizations (ACOs)

Pulsar TRAC. Big Social Data for Research. Made by Face

Data and Informatics Challenges Survey Results from ACO Leadership

IVF OVERVIEW. Tracy Telles, M.D.

Value of. Clinical and Business Data Analytics for. Healthcare Payers NOUS INFOSYSTEMS LEVERAGING INTELLECT

HIEs as an ACO Infrastructure & Results ICA has Experienced in HIE Deployment

The Big Data Dividend

Note: This article is sponsored by

MSD Information Technology Global Innovation Center. Digitization and Health Information Transparency

NAS Insights Knowledge times 7

Complete Global Cord Blood Banking Industry Report

Job list - Research China

Welcome to chapter 2. The following chapter is called "Indications For IVF". The author is Dr Kamini A. Rao.

Meaningful Use Stage 1:

Great Expectations: Why Pharma Companies Can t Ignore Patient Services

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

McKesson For Better Health

The Data You Need to Evaluate Your Lab Sales Compensation Plan. Sales Compensation in the Laboratory Industry: Incentives, Plans and Strategies

Meaningful Use Requires Meaningful Laboratory Results

Launch Tracking with ZoomRx. A Case Study

Business Analytics Market by Software, by Deployment Type, by End User, by Vertical, and by Geography - Global Forecast to 2019

Transcription:

PRACTICEHWY INTEGRATES REPRODUCTIVE MEDICINE EXPERTISE AND BUSINESS INSIGHT TO PROVIDE REAL-WORLD, EVIDENCE-BASED MARKET INTELLIGENCE FOR MANAGING YOUR PRODUCT S LIFECYCLE. Access to our comprehensive data assets, provides unparalleled insight into the fertility marketplace, strengthening your ability to drive decision making and develop successful commercialization strategies. ACCESS TO ACTIONABLE DATA Our informatics products access and report information based on proprietary data assets, offering a comprehensive view of the fertility landscape. Analysis of the data assets provides the information necessary to make more informed strategic branding and business decisions. EMBRYONIC DEVELOPMENT DATA Analysis of success rates by fresh, frozen, ICSI, donor information, and maturity rate. OUR PROPRIETARY DATA ASSETS INCLUDE: EMR DATA CYCLE DATA EMBRYONIC DEVELOPMENT DATA PGD / PGS DATA DRUG PROTOCOL DATA CLAIMS DATA PHARMACY DATA PGD / PGS DATA Detailed data of Chromosome analysis by cell line. DRUG PROTOCOL DATA Analysis of stimulation protocol by market penetration, overall, practice specific, competitive products and success rates. EMR DATA PracticeHwy developed eivf, a fertility specific electronic health record and practice management solution, which captures comprehensive clinical information on tens of thousands of patients each year. Accessing this timely information enables PracticeHwy Fertility Informatics to provide analytics at clinically detailed levels, laboratory and procedure results, performance status readings, and patterns of care measures. CYCLE DATA Success rates can be identified, sorted and collated for accurate data output to include by doctor, by stimulation protocol, by scientist, by day of the week and by a number of different markers. CLAIMS DATA All billing information within the PracticeHwy affiliated practices is routinely integrated into one common database that contains the complete longitudinal encounter information for patients treated. PHARMACY DATA Pharmacy market penetration by overall, practice specific and doctor specific.

eivf OVERVIEW Today s fertility landscape is changing at a rapid pace due to trends in personalized medicine and the overall economic sustainability of the healthcare environment. Our products provide the most accurate information and tools available to optimize your sales and marketing strategies and maximize return on investments. The clinical information provided in our products are derived from eivf, the proprietary PracticeHwy electronic health record system. eivf PRODUCTS CAN PROVIDE THREE DIFFERENT VIEWS OF THE INFORMATION: MARKET VIEW BY LINE REGIMEN VIEW BY LINE TOTAL MARKET VIEW BY LINE THE FOLLOWING eivf PRODUCTS ARE AVAILABLE TO MEET YOUR SPECIFIC NEEDS: SUCCESS RATE EMBRYONIC DEVELOPMENT PROTOCOL PERFORMANCE PHARMACY UTILIZATION BY PRACTICE SPECIFIC DRUG UTILIZATION eivf BY LINE Is a snapshot offering that can help to strengthen your strategic activities by giving you expanded visibility into the competitive landscape. REGIMEN VIEW BY LINE Provides an unparalleled view of the competitive environment for directing strategic decisions and educational messages, because you will have more information about: - Clinically detailed segmentation by physician - Patterns of care analysis for insight into dosing issues - Market share for drug utilization at clinical segment levels MARKET VIEW Is a single information source that provides a continuous view of your product s market position within the PracticeHwy network. This offering enables the ability to track competitive products at the same level of clinical detail in order to monitor total market penetration at a granular view. TOTAL MARKET VIEW BY LINE is a detailed offering that can: - Identify local markets which are performing above or below expectations allowing you to quickly shift marketing resources - Summarize information within eligible target patients, patients treated by target products and competitive products - Improve oversight of marketing efforts by tracking targeted penetration over time within each line, by account or overall utilization

R MARKET RESEARCH SERVICE Provides your team with detailed demographic, clinical and treatment information for your existing market or for a newly identified target market. This thorough view of the market includes a detailed analysis of the clinical characteristics and the protocols utilized on an identified population. At a strategic level, the Market Research Services offers: - A measure for evaluating current levels of market service by competing lines on an identified market - A basis for measuring performance for a business unit, acquisition target or proposed geographic relationship - A planning element for brand teams preparing for market entry and launching programs The clinical information included in the Market Research Service is derived from eivf, the proprietary software of PracticeHwy EMR. A sampling of the data elements include: PATIENT Age Gender Geographic Payer CLINICAL Diagnosis/staging Performance status Laboratory results Procedure utilization TREATMENT Regimen/cycles Protocol specifics Duration Dosing/dose intensity Discountinuation reasons MARKET SIZING & MARKET SNAPSHOT SUBSCRIPTION Provides your team with detailed demographic, clinical and treatment information for your existing market or for a newly identified target market. This thorough view of the market includes a detailed analysis of the clinical characteristics and the treatment protocols utilized on an identified population. MARKET SIZING Gives insight into the competitive nature of the market for your product, enabling information based allocation of your marketing dollars, by: - Measuring and monitoring timely activity at global or practice level - Providing information on the demographic segments for a product MARKET SNAPSHOT SUBSCRIPTION Provides a targeted view of the overall Fertility market allowing a better prediction of market size and verifying projections for your products. Through this subscription, you can quickly verify the best potential for your clinical strategies, as well as gain calculated input for your R&D spend. The accurate and clinically detailed information provided in the Market snapshot subscription supports your strategic initiatives with measurable data. PracticeHwy can provide high level network patient counts by diagnosis and segmentation in the following areas: - Line - Performance status - Drug utilization - Genetic markers - Age

Below are examples of compiled data for specific targeted protocols: DID PATIENTS CONSUME FEWER HEALTH CARE RESOURCES WHEN THEY WERE ON ANTAGONIST PROTOCOLS COMPARED TO THEIR COUNTERPARTS ON AGONIST PROTOCOLS? Agonist protocol Antagonist protocol NN mean median range mean median range Clinic visits 5,56 6.77 5 1-60 6,003 6.18 5 1-36 Calls to clinic Nurse calls to patient,891 1,88 4.4 4.7 3 3 1-4 1-31,5 1,506 3. 3.63 1-3 1-5 Ultrasound 5,715 5.96 6 1-4 6,73 6.57 6 1-0 Lab tests Procedures Results Communicated Nurse calls to patient & Results Communicated 5,74 5,096 5,494 5,660 8.3.3 6.93 8.15 8 5 7 1-44 1-10 0-8 0-41 6,76 5,89 6,10 6,47 9.7.40 7.73 8.44 8 7 7 1-4 1-1 0-3 0-49 WHAT WERE THE CLINICAL / NON-CLINICAL CHARACTERISTICS OF PATIENTS TREATED WITH AGONIST VS ANTAGONIST PROTOCOLS? Total Obs GnRH agonist GnRH antagonist p-value N Value N Value N 6460 7503 Age 1,618 5,890 35.60 6,78 35.84 0.990 BMI 1,959 5.88 6,499 5.94 0.4080 Smoking Status (yes).74%.60% 0.3935 Parity Status (yes) 8.98% 6.79% 0.9961 Basal FSH 5,97,601 8.1 3,36 7.97 0.6836 Basal AFC 1,884 695 7.57 1,189 7.48 0.9870 Prior IUI 31.84% 38.78% 1.0000 OC pre-treatment 6,08 63.0% 7,138 51.% 1.0000 Endometriosis 11,046 5,060 9.53% 5,986 8.60% 0.9068 PCOS 11,046 5,060 0.69% 5,986 0.45% 0.480 Previous IVF/ICSI cycles 47.35% 44.68% 1.0000 # Previous IVF/ICSI cycles 1.05 1.00 0.939

SALES PERFORMANCE SALES PERFORMANCE products provide you visibility into changes and trends in ordering patterns. DISTRIBUTION ACTIVITIES DATA Provides valuable information that enables you to maximize the efficiency of your sales and marketing efforts through insight into management, such as: - Account penetration - Quantities utilized - Sold date - Overall market share - Geographic INSIGHT Pharma-economic insight offers: - Insight into the real-world economics associated with your product and that of your competitors - Positioning of your product in the market - Clinical performance of your products in the community fertility setting CLINICAL CLINICAL insight allows you to better demonstrate the clinical performance of your products in the marketplace, bridging the gap between clinical efficacy and real world effectiveness. SALES ACTIVITY DATA Provides you with an opportunity to monitor changes in the marketplace for effective allocation of your marketing education dollars. This information ultimately allows you to make decisions for gaining market share and develop targeted sales force compensation models. It also allows you to gain insight into sales of a product or products to the physician through information on: - Location - Volume - Utilization frequency